Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1256482 | 0.89 | AGTR1 (0.49) | AGTR1AGTR2 | |
| SCHEMBL1258420 | 0.88 | AGTR1 (0.47) | AGTR1 | |
| SCHEMBL1258631 | 0.88 | AGTR1 (0.48) | AGTR1AGTR2 | |
| SCHEMBL1257915 | 0.86 | AGTR1 (0.47) | AGTR1 | |
| SCHEMBL1258609 | 0.86 | AGTR1 (0.46) | AGTR1 | |
| SCHEMBL16874985 | 0.86 | AGTR1 (0.49) | AGTR1AGTR2 | |
| SCHEMBL1257881 | 0.85 | AGTR1 (0.46) | AGTR1AGTR2 | |
| SCHEMBL1258092 | 0.85 | AGTR1 (0.46) | AGTR1 | |
| SCHEMBL1258598 | 0.85 | AGTR1 (0.46) | AGTR1 | |
| SCHEMBL1258561 | 0.85 | AGTR1 (0.44) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273008-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-9150514-B2 | Dual-acting antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150191435-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-07-09 | — | — | US | disclosed |
| US-9012485-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-04-21 | — | — | US | disclosed |
| US-20150065543-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-03-05 | — | — | US | disclosed |
| US-8895755-B2 | Intermediates for preparing dual-acting benzyl triazole antihypertensive agents having angiotensin II type I receptor antagonist activity and neprilysin-inhibition activity | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140303222-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-09 | — | — | US | disclosed |
| US-8664254-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE, INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-20140024835-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-8569351-B2 | Dual-acting benzyl triazole antihypertensive agents having angiotensin II type receptor antagonist activity and neprilysin-inhibition activity | THERAVANCE, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8349875-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8344013-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120264752-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-8236846-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20120165381-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20110281925-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-8013005-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7879896-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090023228-A1 | Dual-acting Imidazole antihypertensive agents | THERAVANCE, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20080269305-A1 | R)-N-{2-Butyl-3-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl}-2-(2-hydroxycarbamoyl-3-phenyl-propionylamino)succinamic Acid; AT1 receptor antagonist and neprilysin (NEP) enzyme inhibition activity; hypertension, heart failure | THERAVANCE, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269305-A1 | R)-N-{2-Butyl-3-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl}-2-(2-hydroxycarbamoyl-3-phenyl-propionylamino)succinamic Acid; AT1 receptor antagonist and neprilysin (NEP) enzyme inhibition activity; hypertension, heart failure | AGTR2, REN, AGTR1 | AGTR1 3/4885AGTR2 1/4885 |
| US-20110281925-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR1 1/4885AGTR2 2/4885 |
| US-20150191435-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR1 1/4885AGTR2 2/4885 |
| US-20140303222-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR1 1/4885AGTR2 2/4885 |
| US-20150065543-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR1 1/4885AGTR2 2/4885 |
| US-20090023228-A1 | Dual-acting Imidazole antihypertensive agents | AGTR1, AGTR2, REN | AGTR1 1/4885AGTR2 2/4885 |
| US-20120165381-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR1 1/4885AGTR2 2/4885 |
| US-20120264752-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR1 1/4885AGTR2 2/4885 |
| US-20140024835-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR1 1/4885AGTR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.